Prime Medicine to Participate in Upcoming Investor Conferences
JonesTrading Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $14
Prime Medicine's Promising Gene Editing Advancements Justify Buy Rating
Prime Medicine Advances Gene Editing for Liver Diseases
Express News | Prime Medicine- on Track to Initiate Ind-Enabling Activities for Wilson's Disease Program in 4Q 2024, With Ind and/or Cta Filing Expected in 1H 2026
Prime Medicine Presents In Vivo Proof-of-Concept Data Highlighting Interim Preclinical Advances in Its Wilson's Disease Program and the Broad Potential of Its Universal Liver-Targeted LNP at ESGCT 31st Annual Congress